Skip to main content

New Drug Cladribine for Multiple Sclerosis Shows Promise

  • Synopsis: Published: 2010-01-20 (Revised/Updated 2017-02-13) - Major trial of oral drug Cladribine has shown it significantly reduces relapse and deterioration of multiple sclerosis (MS). For further information pertaining to this article contact: Queen Mary, University of London.

Main Document

Quote: "The introduction of an oral therapy, particularly one that has no short term side effects and is as easy to use as oral Cladribine, will have a major impact on the treatment of MS."

Little pill means big news in the treatment of MS - A new drug for multiple sclerosis promises to change the lives of the 100,000 people in the UK who have the condition, say researchers at Queen Mary, University of London.

A major trial of the oral drug Cladribine - results of which are published in the New England Journal of Medicine on 20 January 2010 - has shown that it significantly reduces relapse and deterioration of the disease, and goes a long way to eliminating the unpleasant side effects associated with existing therapies. Cladribine promises to be the first ever treatment in tablet form for MS, and only needs be taken for between 8 to 10 days a year, eliminating the need for regular injections and intravenous infusions otherwise endured by sufferers. The ease with which Cladribine tablets can be administered, combined with its relatively few side effects, make it a hugely exciting development in the world of MS.

Multiple sclerosis is a disabling neurological condition which usually starts in young adulthood. It results from the body's own immune system damaging the central nervous system. This interferes with the transmission of messages between the brain and other parts of the body and leads to problems with vision, muscle control, hearing and memory. Cladribine tablets work by suppressing the immune system thus compromising its ability to further attack the central nervous system.

Led by Professor Gavin Giovanonni at Barts and The London School of Medicine and Dentistry, the new study involved over 1,300 MS patients who were followed up for nearly two years and monitored using MRI scans. Patients were given either two or four short treatment courses of Cladribine tablets per year, or a placebo. Each course consists of one or two tablets per day for four or five days, adding up to just eight to 20 days of treatment each year.

Compared to patients who were taking a placebo, those taking Cladribine tablets were over 55 per cent less likely to suffer relapse, and 30 per cent less likely to suffer worsening in their disability due to MS.

Professor Giovanonni said: "The introduction of an oral therapy, particularly one that has no short term side effects and is as easy to use as oral Cladribine, will have a major impact on the treatment of MS."

"However, the use of this drug as a first line therapy will have to be weighed up against the potential long term risks which have yet to be defined."

'A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis' is published online in the New England Journal of Medicine on Wednesday 20 January 2010, and in print on 4 February 2010.

Related Information:

  1. Cladribine Significantly Reduces Brain Atrophy in Patients with Multiple Sclerosis - Phase III CLARITY study data revealed significant reduction in brain atrophy in patients on short course of investigational Cladribine Tablets over two years - EMD Inc.
  2. Extension of FDA Review for Cladribine Tablets for Treatment of Relapsing Forms of Multiple Sclerosis - EMD Serono Announces Extension of FDA Priority Review Period for Cladribine Tablets for the Treatment of Relapsing Forms of Multiple Sclerosis - EMD Serono, Inc.
  3. Ocrelizumab Shows Significant Reduction in Multiple Sclerosis Disease Activity - Phase II Study with Ocrelizumab Shows Significant Reduction in Disease Activity for Multiple Sclerosis Patients - Multiple Sclerosis News


Information from our Multiple Sclerosis: Subtypes, Symptoms, Diagnosis and Treatment section - (Full List).

E-Newsletter

Loan Information for low income singles, families, seniors and disabled. Includes home, vehicle and personal loans.


Famous People with Disabilities - Well known people with disabilities and conditions who contributed to society.


List of awareness ribbon colors and their meaning. Also see our calendar of awareness dates.


Blood Pressure Chart - What should your blood pressure be. Also see information on blood group types and compatibility.


  1. FDA Issues Guidance on Generic Abuse-Deterrent Opioid Development
  2. Getting a Job with a Disability - Infographic with Transcript
  3. New Sports and Disciplines for Paris 2024 Paralympics
  4. Video Game Improves Balance in Youth With Autism




Citation